Zeneca Files NDA for Arimidex

July 1, 1995

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application (NDA) for the use of Arimidex (anastrozole) tablets for the treatment of advanced breast cancer in postmenopausal women who have progressed following therapy with tamoxifen (Nolvadex).

WILMINGTON, Del--Zeneca Pharmaceuticals has filed a new drug application(NDA) for the use of Arimidex (anastrozole) tablets for the treatmentof advanced breast cancer in postmenopausal women who have progressedfollowing therapy with tamoxifen (Nolvadex).

Arimidex, a nonsteroidal compound, is one of the first of a newclass of selective oral aromatase inhibitors, designed to reducethe production of estrogen. The NDA is based on randomized, controlledtrials involving 764 women with advanced breast cancer, the companysaid.